009. KALLIKREIN-RELATED PROTEASES AS NOVEL THERAPEUTIC TARGETS IN PROSTATE AND OVARIAN CANCER
J. A. Clements A B , Y. Dong B , D. Loessner B , O. Tan B , S. Sieh C , J. Reichert C , L. Burke B , C. Stephens A B , M. Lawrence A B , S. Stansfield A B , J. Swedberg A B , A. Ramsay A B , J. Hooper A B , J. Harris A B and D. Hutmacher CA Australian Prostate Cancer Research Centre-Queensland at Princess Alexandra Hosp, Queensland University of Technology, QLD, Australia
B Hormone Dependent Cancer Program, Institute of Health and Biomedical Innovation, QLD, Australia
C Regenerative Medicine Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, QLD, Australia
Reproduction, Fertility and Development 21(9) 000-000 https://doi.org/10.1071/SRB09Abs009
Published: 26 August 2009
Abstract
The kallikrein-related (KLKs) peptidases are implicated in prostate and ovarian cancer invasion/metastasis via activation of growth factors, proteases and extracellular matrix degradation involved in. In our published work, we used cell biology approaches to show novel associations of KLK peptidases with processes indicative of metastasis and the potential of our novel sunflower trypsin inhibitor scaffold-engineered KLK4 inhibitor. Our current studies are directed towards discovering the precise KLK target proteins/substrates and the subsequent signalling pathways involved in these events in order to determine their therapeutic target potential. In this regard, we are using novel tissue engineered biomimetic 3D gel matrices to better mimic the in vivo micro-environment of prostate cancer cells especially in bone metastasis and peritoneal invasion in ovarian cancer. Pilot studies show that PC3 cells cultured on an osteoblast-derived bone matrix undergo an EMT-like change but remain dispersed on the cell surface. In contrast, LNCaP cells cluster aligning with the fibrillar structure as they invade into the bone matrix as typically seen in vivo. KLK4 proteolysis of the osteoblast-derived bone matrix has identified additional novel substrates. In addition, we are exploring the cell biology that underlies the reported high KLK4 or KLK7 levels associated with poorer outcome in women with epithelial ovarian cancer (EOC). Of note, KLK4 or KLK7 transfected SKOV3 EOC cells have increased chemoresistance to taxol and/or cisplastin suggesting a mechanism for this poor outcome. Furthermore, KLK7 transfected SKOV-3 cells form multicellular aggregates (MCA) in agarose suspension (a process indicative of peritoneal tumour cell spread seen in ascites fluid clinically) which can be reversed by a KLK7 blocking antibody indicating the critical role played by KLK7 in this event. These new paradigms are providing novel information on the role of KLK peptidases in prostate and ovarian cancer progression and their potential as novel therapeutic targets.
